eMedicine Specialties > Rheumatology > Spondyloarthropathies

Enteropathic Arthropathies

Author: Pierre Minerva, MD, Consulting Staff, Department of Rheumatology, Bryn Mawr Medical Specialists Association; Consulting Staff, Department of Rheumatology, Bryn Mawr Hospital, Lankenay Hospital, Paoli Hospital
Contributor Information and Disclosures

Updated: Dec 5, 2008

Introduction

Background

Enteropathic arthropathies comprise a collection of rheumatologic conditions that share a link to GI pathology. These conditions include reactive (ie, infection-related) arthritis caused by bacteria (eg, Shigella, Salmonella, Campylobacter, Yersinia species, Clostridium difficile), parasitic infections (eg, Strongyloides stercoralis, Giardia lamblia, Ascaris lumbricoides, Cryptosporidium species), and spondyloarthropathies associated with inflammatory bowel disease (IBD), Crohn disease, and ulcerative colitis.

Other associated conditions and disorders include intestinal bypass (jejunoileal) arthritis, celiac disease, Whipple disease, and collagenous colitis.

Pathophysiology

The precise causes of enteropathic arthropathies are unknown. Inflammation of the GI tract may increase permeability, resulting in absorption of antigenic material, including bacterial antigens. These arthrogenic antigens may then localize in musculoskeletal tissues (including entheses and synovium), thus eliciting an inflammatory response. Alternatively, an autoimmune response may be induced through molecular mimicry, in which the host's immune response to these antigens cross-reacts with self-antigens in synovium and other target organs.

Of particular interest is the strong association between reactive arthritis and HLA-B27, an HLA class I molecule. A potentially arthrogenic, bacterially derived antigen peptide could fit in the antigen-presenting groove of the B27 molecule, resulting in a CD8+ T-cell response. HLA-B27 transgenic rats develop features of enteropathic arthropathy with arthritis and gut inflammation.

Frequency

United States

Arthritis is the most common extraintestinal manifestation of IBD, with approximately 10%-20% of individuals with IBD developing peripheral arthritis and/or sacroiliitis/spondylitis. The incidence of ulcerative colitis is 6-8 cases per 100,000 population per year, and the prevalence is 70-150 cases per 100,000 population. The incidence of Crohn disease is 2 cases per 100,000 population per year, and the prevalence is 20-40 cases per 100,000 population. The incidence of IBD and, particularly, Crohn disease is increasing.

International

The incidence and prevalence rates of ulcerative colitis and Crohn disease in northern and Western Europe are similar to those in the United States, but rates are lower in other regions of the world.

Race

  • The incidence of IBD is higher in whites, especially those of Jewish descent, than in other racial groups.

Sex

  • The peripheral arthritis of ulcerative colitis or Crohn disease does not have a sexual predilection.
  • Spondylitis is more common in males than in females.
  • Whipple disease is more common in men, with a male-to-female ratio of 9:1.

Age

  • IBD is most common in persons aged 15-35 years.

Clinical

History

  • Axial arthritis (sacroiliitis and spondylitis) in inflammatory bowel disease (IBD)
    • Insidious onset of low back pain, especially in younger persons
    • Morning stiffness
    • Exacerbated by prolonged sitting or standing
    • Improved by moderate activity
    • Independent of GI symptoms
  • Peripheral arthritis in IBD (colitic arthritis)
    • Oligoarticular
    • Asymmetric, predominantly involving the lower extremities
    • Associated with GI symptoms
    • Frequently transient and migratory, occasionally additive
    • More common in Crohn disease than ulcerative colitis
    • May precede intestinal involvement, but usually concomitant or subsequent to bowel disease
  • Enthesitis
    • Heel - Insertion of Achilles tendon and plantar fascia
    • Knee - Tibial tuberosity, patella
    • Others - Buttocks, foot
  • Extra-articular IBD
    • Intestinal - Abdominal pain, weight loss, diarrhea, and hematochezia
    • Skin -Pyoderma gangrenosum (ulcerative colitis), erythema nodosum (Crohn disease)
    • Oral -Aphthous ulcers (ulcerative colitis, Crohn disease)
    • Ocular - Acute anterior uveitis
    • Systemic low-grade fever, secondary amyloidosis (Crohn disease)
  • Reactive arthritis
    • Typically an acute asymmetric oligoarthritis
    • Knees and/or ankles
    • Appears up to several weeks after the initial enteric infection (certain species of Yersinia, Salmonella, Shigella, Campylobacter, among others)
  • Intestinal bypass arthritis
    • This is a procedure introduced for morbid obesity (jejunocolostomy or jejunoileostomy).
    • Arthritis develops in 20-80% of patients 2-30 months after surgery and is chronic in 25% of cases.
    • Polyarthritis may occur.
    • Dermatitis is associated in 66-80% of cases.
    • The proposed mechanism is bacterial overgrowth in the bypassed bowel, which causes inflammation and synthesis of immune complexes.
    • Reversal of procedure produces permanent remission of symptoms.
  • Celiac disease
    • Gluten-sensitive enteropathy
    • Arthritis uncommon
    • May precede diagnosis of celiac disease
    • Lumbar spine, hips, knees, shoulders
    • Usually symmetrical
    • Improves with gluten-free diet
  • Collagenous colitis
    • Unknown cause
    • Linear deposition of collagen in the subepithelial layer of the colon
    • Watery diarrhea and colicky abdominal pain
    • Peripheral arthritis of hands and wrists, which may precede GI symptoms by years (10% of cases)
    • Arthritis improved by nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Whipple disease
    • Rare, multisystemic
    • Caused by infection with Tropheryma whippleii
    • Most common in middle-aged men
    • Diarrhea, weight loss, and malabsorption
    • Migratory polyarthritis in as many as 90% of cases, which may precede GI symptoms by years
    • Sacroiliitis (occasional)
    • Diagnosis via small-bowel biopsy
    • Symptoms improved by prolonged courses of antibiotics (eg, penicillin, tetracycline, erythromycin)

Physical

  • Articular
    • Examine the joints for signs of inflammation and note the pattern and symmetry of involvement.
    • Test the spine for range of motion, flexibility, and sacroiliac tenderness.
    • Look for periarticular soft-tissue swelling and/or tenderness, especially at the heel (eg, enthesitis).
  • Skin - Look for pyoderma gangrenosum (ulcerative colitis) and erythema nodosum (Crohn disease).
  • Eyes - Look for acute anterior uveitis or conjunctivitis.

Causes

  • Causes are unknown but are probably related to immune-mediated inflammation (see Pathophysiology).
  • Sacroiliitis is associated with HLA-B27 (40%).
  • Spondylitis associated is with HLA-B27 (60%).
  • HLA-B27 is not associated with peripheral arthritis with the exception of reactive arthritis (80%).

More on Enteropathic Arthropathies

Overview: Enteropathic Arthropathies
Differential Diagnoses & Workup: Enteropathic Arthropathies
Treatment & Medication: Enteropathic Arthropathies
Follow-up: Enteropathic Arthropathies
References

References

  1. Hoffman IE, Demetter P, Peeters M, et al. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. May 2003;62(5):455-9. [Medline].

  2. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. Dec 2004;63(12):1664-9. [Medline].

  3. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. Mar 2002;46(3):755-65. [Medline].

  4. Brophy S, Pavy S, Lewis P, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol. Dec 2001;28(12):2667-73. [Medline].

  5. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am. Nov 1998;24(4):785-813, ix-x. [Medline].

  6. Fomberstein B, Yerra N, Pitchumoni CS. Rheumatological complications of GI disorders. Am J Gastroenterol. Jun 1996;91(6):1090-103. [Medline].

  7. Grigoryan M, Roemer FW, Mohr A, et al. Imaging in spondyloarthropathies. Curr Rheumatol Rep. Apr 2004;6(2):102-9. [Medline].

  8. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. Dec 2006;65(12):1631-4. [Medline].

  9. Holden W, Orchard T, Wordsworth P. Enteropathic arthritis. Rheum Dis Clin North Am. Aug 2003;29(3):513-30, viii. [Medline].

  10. Karimi O, Pena AS. Indications and challenges of probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease. J Clin Gastroenterol. Sep 2008;42 Suppl 3 Pt 1:S136-41. [Medline].

  11. Katz JP, Lichtenstein GR. Rheumatologic manifestations of gastrointestinal diseases. Gastroenterol Clin North Am. Sep 1998;27(3):533-62, v. [Medline].

  12. Mielants H, Veys EM. Enteropathic arthropathis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 4th. Mosby Elsevier; 2008:1189-1195 / 113.

  13. Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med. Jun 2005;118(6):592-603. [Medline].

  14. Szpalski M, Gunzburg R. What are the advances for surgical therapy of inflammatory diseases of the spine?. Best Pract Res Clin Rheumatol. Jan 2002;16(1):141-54. [Medline].

  15. Wollheim FA. Enteropathic arthritis: how do the joints talk with the gut?. Curr Opin Rheumatol. Jul 2001;13(4):305-9. [Medline].

  16. Wright V. Enteropathic arthritis. Cleve Clin J Med. Jan-Feb 1994;61(1):14-6; quiz 80-2. [Medline].

Further Reading

Keywords

enteropathic arthropathy, enteropathic arthropathies, reactive arthritis, Shigella, Salmonella, Campylobacter, Yersinia, Clostridium difficile, C difficile, intestinal parasites, Strongyloides stercoralis, S stercoralis, Taenia saginata, T saginata, Giardia lamblia, G lamblia, Ascaris lumbricoides, A lumbricoides, Cryptosporidium, inflammatory bowel disease, Crohn disease, Crohn’s disease, IBD, jejunoileal intestinal bypass, celiac disease, Whipple disease, Whipple’s disease, collagenous colitis, HLA-B27, sacroiliitis, spondylitis, peripheral arthritis, colitic arthritis, axial arthritis, sacroiliitis, spondylitis

Contributor Information and Disclosures

Author

Pierre Minerva, MD, Consulting Staff, Department of Rheumatology, Bryn Mawr Medical Specialists Association; Consulting Staff, Department of Rheumatology, Bryn Mawr Hospital, Lankenay Hospital, Paoli Hospital
Pierre Minerva, MD is a member of the following medical societies: American College of Rheumatology
Disclosure: Nothing to disclose.

Medical Editor

Kristine M Lohr, MD, MS, Program Director, Professor, Department of Internal Medicine, Division of Rheumatology and Women's Health, University of Kentucky School of Medicine
Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians, American College of Rheumatology, and American Medical Women's Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Lawrence H Brent, MD, Associate Professor of Medicine, Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center
Lawrence H Brent, MD is a member of the following medical societies: American Association of Immunologists, American College of Physicians, and American College of Rheumatology
Disclosure: Genentech Honoraria Speaking and teaching; Genentech Grant/research funds Other; Amgen Honoraria Speaking and teaching; Wyeth Honoraria Speaking and teaching; Abbott Immunology Honoraria Speaking and teaching

CME Editor

Alex J Mechaber, MD, FACP, Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine
Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD, Professor of Medicine, Temple University School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital
Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa
Disclosure: medifocus Honoraria Review panel membership; health dialogs Honoraria Consulting; Merck, Amgen, Biogen, Zimmer, Wyeth, Johnson&Johnson, Stryker, Medtronic, Zimmer.Abbott,  Ownership interest Other; West Penn Allegheny Health System Consulting fee Consulting; Alpharma Honoraria Consulting; Proctor&Gamble Grant/research funds Independent contractor

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.